We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

57 hedge funds and large institutions have $261M invested in KalVista Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

70% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 10

19% more funds holding

Funds holding: 48 → 57 (+9)

4.16% more ownership

Funds ownership: 73.12% → 77.28% (+4.2%)

6% less capital invested

Capital invested by funds: $278M → $261M (-$16.5M)

Holders
57
Holders Change
+9
Holders Change %
+18.75%
% of All Funds
1.27%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.16%
New
17
Increased
17
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$5.93M
2
Invesco
Invesco
Georgia
+$5.56M
3
GTC
Ghost Tree Capital
New York
+$4.02M
4
FI
Fosun International
China
+$2.76M
5
PC
Polar Capital
United Kingdom
+$1.59M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$7.16M
2
FCM
Farallon Capital Management
California
-$4.42M
3
SCM
Stonepine Capital Management
Oregon
-$3.05M
4
Millennium Management
Millennium Management
New York
-$1.15M
5
SHI
SV Health Investors
Massachusetts
-$629K
Name Holding Trade Value Shares
Change 		Change in
Stake
Susquehanna International Group
26
Susquehanna International Group
Pennsylvania
$944K +$961K +47,821 New
BlackRock
27
BlackRock
New York
$891K +$518K +25,769 +133%
EI
28
EAM Investors
California
$827K – – –
WMSA
29
Weiss Multi-Strategy Advisers
New York
$810K +$20.1K +1,000 +3%
Northern Trust
30
Northern Trust
Illinois
$805K +$202K +10,034 +33%
JP Morgan Chase
31
JP Morgan Chase
New York
$727K +$627K +31,183 +556%
Wells Fargo
32
Wells Fargo
California
$682K +$150K +7,451 +28%
LCM
33
Laurion Capital Management
New York
$596K +$607K +30,201 New
TI
34
Telemetry Investments
New York
$491K +$179K +8,883 +56%
DCM
35
DAFNA Capital Management
California
$399K +$50.3K +2,500 +14%
AG
36
Algert Global
California
$382K +$389K +19,341 New
SAM
37
Sectoral Asset Management
Quebec, Canada
$347K – – –
OAM
38
Oxford Asset Management
United Kingdom
$236K +$241K +11,967 New
Dimensional Fund Advisors
39
Dimensional Fund Advisors
Texas
$220K -$25.1K -1,250 -10%
Bank of Montreal
40
Bank of Montreal
Ontario, Canada
$90K +$91.1K +4,532 New
Bank of America
41
Bank of America
North Carolina
$87K +$83.4K +4,149 +1,693%
FQ
42
First Quadrant
California
$60K – – –
TAM
43
Tiverton Asset Management
Delaware
$50K +$50.5K +2,512 New
RQS
44
Ramsey Quantitative Systems
Kentucky
$35K +$36K +1,789 New
FCM
45
Flinton Capital Management
Pennsylvania
$26K +$26K +1,292 New
TAM
46
Tyers Asset Management
Texas
$21K +$21.4K +1,064 New
Morgan Stanley
47
Morgan Stanley
New York
$17K -$67.4K -3,352 -80%
NA
48
Neuburgh Advisers
California
$17K +$16.8K +836 New
DWA
49
Dorsey Wright & Associates
California
$17K +$17.3K +862 New
PCM
50
Prelude Capital Management
New York
$12K -$1.19K -59 -9%
1
2
3

KALV Hedge Fund Activity: Q4 2018 in Review

57 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q4 2018, worth a combined $261M — down 5.9% from $278M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KALV positions and 8 closed out — a net gain of 9 holders — while 17 added to existing stakes and 10 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $5.93M. The largest seller was BVF Inc, cutting an estimated $7.16M.

  • 57 institutional investors held KalVista Pharmaceuticals (KALV) as of Q4 2018, up from 48 in Q3 2018.
  • Funds reported $261M of KalVista Pharmaceuticals stock for Q4 2018, down 5.9% quarter-over-quarter.
  • 17 funds opened new KalVista Pharmaceuticals positions in Q4 2018 and 8 closed out, a net change of +9 holders.
  • The largest KalVista Pharmaceuticals buyer in Q4 2018 was Adage Capital Partners, an estimated $5.93M added.
  • The largest KalVista Pharmaceuticals seller in Q4 2018 was BVF Inc, an estimated $7.16M sold.

Based on aggregated 13F filings for Q4 2018.